1. Home
  2. BMEA vs JLS Comparison

BMEA vs JLS Comparison

Compare BMEA & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$0.60

Market Cap

92.1M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

N/A

Current Price

$16.12

Market Cap

90.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BMEA
JLS
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
92.1M
90.1M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
BMEA
JLS
Price
$0.60
$16.12
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $6.57
N/A
AVG Volume (30 Days)
★ 2.2M
26.3K
Earning Date
11-03-2026
01-01-0001
Dividend Yield
N/A
★ 9.33%
EPS Growth
★ 69.19
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$16.01
52 Week High
$2.24
$18.94

Technical Indicators

Market Signals
Indicator
BMEA
JLS
Relative Strength Index (RSI) 22.67 36.66
Support Level N/A $16.01
Resistance Level $1.47 $16.57
Average True Range (ATR) 0.11 0.18
MACD -0.06 0.00
Stochastic Oscillator 2.92 10.89

Price Performance

Historical Comparison
BMEA
JLS

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.

Share on Social Networks: